ORYZON to Give Updates on Corporate Progress in March and April
Virtual Bio-Europe Spring 2022Kempen Life Sciences Conference Asebio Investor Day MADRID, Spain and CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) --...
ORYZON Announces FDA Approval of IND for FRIDA, a Phase Ib Trial With Iadademstat in R/R AML FLT3mut+ Patients
In combination with gilteritinibPrimary objectives: to assess safety, tolerability and RP2DSecondary objectives: to assess efficacy MADRID, Spain and...